XELIRI+ bevacizumab

2 trials

Sponsors

Epidemiological and Clinical research Information Network (ECRIN), Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group

Conditions

colorectal cancer

Phase 1

A Phase I /II Study of Tri-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy.

Active, not recruitingJPRN-UMIN000003482

Epidemiological and Clinical research Information Network (ECRIN)colorectal cancer

Start: 2010-05-01Target: 33Updated: 2026-06-29

To decide Recommended dose of XELIRI and bevacizumab in patients with metastatic colorectal cancer who have oxlplatin based first-line chemotherapy including treatment failure or refractory, and To evaluate the safety and efficacy -PhaseI/II Study

Active, not recruitingJPRN-UMIN000003934

Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Groupcolorectal cancer

Start: 2010-07-01Target: 51Updated: 2026-06-29

Related Papers

Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.

2017-05-166 citations